Income Statement (Annual)

WLH / Lyon William Homes Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Adminstrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.

All numbers are times 1,000 except per share units.

2013 2014 2015 2016 2017
Revenues
  Home Building Revenue 521,310 857,025 1,078,928 1,402,203 1,795,074
  Construction Revenue 32,533 37,728 25,124 3,837 1,454
  Revenues 572,535 894,753 1,106,552 1,406,040 1,796,528
Operating Expenses
  Home Building Costs 405,496 677,531 878,995 1,162,337 1,478,549
  Construction And Development Costs 25,598 30,700 21,181 3,485 1,317
  Selling And Marketing Expense 26,102 45,903 61,539 72,509 86,226
  General And Administrative Expense 40,770 54,626 59,161 73,398 90,206
  Business Combination Acquisition Related Costs 0 5,832 0 0 -
  Other Expenses 2,166 2,874 1,972 343 2,274
  Operating Expenses 516,678 819,280 1,025,534 1,312,072 1,658,572
Operating Income Loss 55,857 75,473 81,018 93,968 137,956
Income Loss From Equity Method Investments 0 555 3,239 5,606 3,700
Other Nonoperating Income Expense 510 2,295 2,810 3,243 895
Income Lossfrom Continuing Operationsbefore Extinguishmentofdebt Equitymethodinvestmentsincometaxesnoncontrollinginterest - - 87,067 102,817 142,512
Gains Losses On Extinguishment Of Debt 203,000 - 0 0 -21,828
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments 53,301 78,323 87,067 102,817 120,684
Income Tax Expense Benefit -82,302 23,797 26,806 34,850 62,933
Profit Loss 135,603 54,526 60,261 67,967 57,751
Net Income Loss Attributable To Noncontrolling Interest 6,471 9,901 2,925 8,271 9,616
Net Income Loss 129,132 44,625 57,336 59,696 48,135
Earnings Per Share
  Earnings Per Share Basic 0 0 0 0 0
  Earnings Per Share Diluted 0 0 0 0 0
Weighted Average Common Shares Outstanding
  Weighted Average Number Of Shares Outstanding Basic 24,737 31,753 36,546 36,765 37,040
  Weighted Average Number Of Diluted Shares Outstanding 25,796 33,236 38,768 38,475 38,664

Peers - Operative Builders (1531)

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

12h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

13h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 552074700